SAANDSelective Apoptotic Anti-Neoplastic Drug
References in periodicals archive ?
CP461, a second-generation SAAND with a dual mechanism of action, is currently under study as a single-agent for the potential treatment of chronic lymphocytic leukemia, hormone-refractory prostate cancer, and advanced kidney cancer.
SAANDs selectively trigger apoptosis in cancerous and precancerous cells by inhibiting certain cyclic GMP phosphodiesterases that company scientists and collaborators have shown to be over-expressed in a variety of tumor types.
Moreover, any profits from its sale will provide capital to help reduce the company's overall burn rate and support the further development of the company's SAANDs technology," concluded Towarnicki.
Moreover, CP461 is demonstrating strong anticancer activity on its own and we have even more potent SAAND compounds in preclinical stages of development.
In particular, we are developing a novel family of compounds called selective apoptotic antineoplastic drugs, or SAANDs, that we believe hold promise for selectively killing cancer cells without the typical toxicities of conventional chemotherapeutic agents.
Towarnicki explained: "We are currently conducting clinical trials with two of our SAANDs.
Cell Pathways scientists and their collaborators have demonstrated that SAANDs exert their apoptotic effects by inhibiting certain cyclic GMP phosphodiesterases that are over-expressed in a variety of tumor types.
Towarnicki continued, "During 2002, our goals remain focused on our mission to develop our SAANDs technology for the treatment of cancer and to build on the progress made during 2001 toward the commercialization of our compounds.
Cell Pathways is conducting clinical studies with Aptosyn(TM) (exisulind), its first-generation SAAND, in combination with conventional chemotherapeutic drugs in a variety of clinical indications.
These results, combined with the abundance of positive cell culture, animal and clinical studies, continue to support our SAANDs technology.
Our SAANDs clinical development program is currently focused on registration-directed trials in cancer indications -- where we believe we can more effectively and efficiently advance the company's compounds towards commercialization.
CP461 is a second-generation SAAND compound, designed to treat cancer by selectively triggering programmed cell death, or apoptosis, in precancerous and cancer cells but not normal cells.